Spruce Biosciences SPRB Income Statement (2019-2026)

NASDAQ SPRB
$51.99 -0.97 (-1.83%)
At close: Aug 20, 2026 · 4:00 PM EDT
Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
0.31M0.31M0.31M0.31M0.31M0.31M0.43M0.54M0.54M0.55M0.55M0.55M0.55M0.56M0.56M0.56M0.56M0.77M1.37M2.87M
Revenue & cost
Revenue (Quarter)
2.00M2.20M3.07M2.90M2.00M1.61M0.60M0.70M
Operating items
Research & Development (Quarter)
8.61M6.26M8.51M9.06M8.79M8.84M11.71M13.13M13.49M11.10M10.32M8.09M6.55M21.46M10.84M-0.43M5.01M4.10M7.58M12.16M
Selling, General & Administrative (Quarter)
2.79M2.88M3.23M2.82M2.77M3.27M3.45M3.01M3.24M2.95M4.32M3.56M3.46M3.31M3.65M3.12M3.22M7.00M4.41M4.35M
Operating Expenses (Quarter)
11.40M9.13M11.73M11.88M11.56M12.11M15.16M16.14M16.73M14.05M14.63M11.65M10.01M24.77M14.49M2.69M8.23M11.10M11.99M16.51M
Operating Income (Quarter)
-11.40M-9.13M-11.73M-11.88M-11.56M-12.11M-13.20M-13.97M-13.66M-11.16M-12.63M-10.04M-9.41M-24.07M-14.49M-2.69M-8.23M-11.10M-11.99M-16.51M
EBIT (Quarter)
-11.40M-9.13M-11.73M-11.88M-11.56M-12.11M-13.20M-13.97M-13.66M-11.16M-12.63M-10.04M-9.41M-24.07M-14.49M-2.69M-8.23M-11.10M-11.99M-16.51M
Non-operating items
Interest & Investment Income (Quarter)
0.04M-0.26M0.06M-0.15M0.27M2.21M0.37M0.13M0.05M0.00M1.10M0.94M0.81M0.57M0.33M0.65M0.04M-0.04M0.49M0.77M
Other Non Operating Income (Quarter)
0.04M0.04M0.06M0.10M0.54M1.27M1.42M1.10M0.94M0.81M
Net income details
EBT (Quarter)
-18.50M-9.62M-12.19M-12.44M-12.16M-10.10M-13.05M-13.97M-13.72M-11.27M-11.62M-9.18M-8.67M-23.48M-14.20M-2.07M-8.21M-11.12M-21.64M-25.26M
Profit After Tax (Quarter)
-11.45M-9.17M-11.76M-11.87M-11.43M-10.46M-12.79M-12.82M-12.35M-10.51M-11.62M-9.18M-8.67M-23.56M-14.04M-2.07M-8.21M-14.67M-12.30M-16.23M
Income from Non-Controlling Interests (Quarter)
0.01M0.02M-0.51M-0.15M-0.03M0.69M
Income from Continuing Operations (Quarter)
-18.50M-9.62M-12.19M-12.44M-12.16M-10.10M-13.05M-13.97M-13.72M-11.27M-11.62M-9.18M-8.67M-23.48M-14.20M-2.07M-8.21M-11.12M-21.64M-25.26M
Consolidated Net Income (Quarter)
-18.50M-9.62M-12.19M-12.44M-12.16M-10.10M-13.05M-13.97M-13.72M-11.27M-11.62M-9.18M-8.67M-23.48M-14.20M-2.07M-8.21M-11.12M-21.64M-25.26M
Income towards Parent Company (Quarter)
-18.50M-9.62M-12.19M-12.44M-12.16M-10.10M-13.05M-13.97M-13.72M-11.27M-11.62M-9.18M-8.67M-23.48M-14.20M-2.07M-8.21M-11.12M-21.64M-25.26M
Net Income towards Common Stockholders (Quarter)
-18.50M-9.62M-12.19M-12.44M-12.16M-10.10M-13.05M-13.97M-13.72M-11.27M-11.62M-9.18M-8.67M-23.48M-14.20M-2.07M-8.21M-11.12M-21.64M-25.26M
Additional items
EPS (Basic) (Quarter)
-59.40-30.90-38.94-39.74-38.73-32.20-30.68-25.84-25.29-21.95-21.22-16.73-15.75-42.68-24.24-3.50-14.58-14.51-15.77-18.41
EPS (Diluted) (Quarter)
-59.40-30.90-38.94-39.74-38.73-32.20-30.68-25.84-25.29-21.95-21.22-16.73-15.75-42.68-24.24-3.50-14.58-14.51-15.77-18.41
Shares Outstanding (Quarter)
0.31M0.31M0.31M0.31M0.31M0.31M0.43M0.54M0.54M0.51M0.55M0.55M0.55M0.55M0.59M0.59M0.56M0.77M1.37M1.37M
Shares Outstanding (Diluted) (Quarter)
0.31M0.31M0.31M0.31M0.31M0.31M0.43M0.54M0.54M0.51M0.55M0.55M0.55M0.55M0.59M0.59M0.56M0.77M1.37M1.37M
EBITDA (Quarter)
-11.40M-9.13M-11.73M-11.88M-11.56M-12.11M-13.20M-13.97M-13.66M-11.16M-12.63M-10.04M-9.41M-24.07M-14.49M-2.69M-8.23M-11.10M-11.99M-16.51M
Interest Expenses (Quarter)
7.14M0.22M0.52M0.41M0.87M0.20M0.22M0.13M0.12M0.11M0.10M0.08M0.07M-0.03M0.04M0.03M0.02M-0.02M10.14M9.51M